Evolocumab compared with placebo in people having surgery for abdominal aortic aneurysm
Tests evolocumab versus placebo on aorta tissue in people having abdominal aortic aneurysm repair.
Key facts
- Who runs it
- University of Pennsylvania
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
- Status
- Not yet recruiting
- Phase
- Early phase 1
- People taking part
- 44 people, planned
- Starts
- 1 Dec 2026
- Expected to end
- 28 Feb 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Evolocumab
- Placebo
- Record updated
- 20 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an abdominal aortic aneurysm (a bulge in the main belly artery) who need open surgery to repair it. It tests whether evolocumab, which lowers LDL cholesterol, changes the aorta's tissue and cells, compared with placebo.
- Age
- Over 18 years
- Sex
- All sexes
- Disease stage
- Abdominal aortic aneurysm that needs open surgical repair.
- Earlier treatment
- You cannot join if you used a PCSK9 inhibitor (evolocumab, alirocumab, inclisiran) within 6 months before the baseline visit.
- Biomarker or test result
- LDL-C must not be below 40 mg/dL (1 mmol/L) (measured within 3 months of the baseline visit).
Main reasons for not taking part
- Aortic dissection, vascular connective tissue disorders, vasculitis or inflammatory aneurysm, or Type I-III or V thoraco-abdominal aortic aneurysm
- Pregnant or breastfeeding women
- Poorly controlled diabetes (A1C > 10% (86 mmol/mol))
- Chronic kidney disease Stage 4/5 or kidney failure on hemodialysis; liver disease (ALT or AST > 3.0 x upper limit of normal)
- Allergy to PCSK9 inhibitors or to latex or natural rubber
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Abdominal aortic aneurysm (AAA) requiring open surgical repair
- Age > 18
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
Who cannot take part
- Prior use of a PCSK9 inhibitor (evolocumab, alirocumab, inclisiran) within 6 months of the baseline visit
- Treatment with another investigational product within 30 days or 5 half-lives of the investigation drug before consent (whichever is longer) that would have an impact on endpoints associated with this trial
- Known allergy to PCSK9 inhibitor
- Vascular connective tissue disorders
- Poorly controlled diabetes (A1C > 10%)
- Chronic kidney disease Stage 4/5 or End Stage Renal Disease (ESRD) on hemodialysis (HD)
- Known latex or naturally rubber allergy
- Any other condition that the Investigator feels prohibits participants' ability to comply with study or follow up
- LDL-C < 40 mg/dL (within 3 months of baseline visit)
- Liver Disease (alanine transaminase [ALT] or aspartate aminotransferase [ALT] > 3.0 x upper limits of normal) (within 3 months of baseline visit)
- Aortic dissection
- Type I-III or V Thoraco-abdominal Aortic Aneurysm
- Vasculitis or inflammatory aneurysm
- Pregnant or lactating women
Where in United States
- Hospital of the University of PennsylvaniaPhiladelphia, United StatesContact: Scott Damrauer, MDNot yet recruiting
About the trial
What the trial wants to find out
The goal of this mechanistic clinical trial is to assess whether lowering the low-density lipoprotein cholesterol (LDL-C) levels in the blood with the injections of the medication evolocumab will have any effect on the tissue or cells of patients with abdominal aortic aneurysm (AAA). Researchers will compare participants receiving evolocumab injections to participants receiving placebo injections to see how the tissue and cells of the aorta are affected by changes in LDL-C levels.
The 2 groups in the trial
- EvolocumabTreatment being tested
Evolocumab is the drug that will be administered in this study. It will be administered as a 140mg subcutaneous injection every 14 days for 5 weeks (for a total of 3 doses).
- PlaceboPlacebo, for comparison
This arm is a matching placebo that will be administered in the same fashion as the study drug if the patient is randomized to placebo.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized, Placebo-Controlled Mechanistic Clinical Trial of PCSK9 Inhibition With Evolocumab in Patients Undergoing Open Abdominal Aortic Aneurysm Repair
- Plain-language title
- Evolocumab compared with placebo in people having surgery for abdominal aortic aneurysmGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 20 April 2026